Providing your location allows us to show you nearby locations and doctors.

Cancer Clinical Trials

Find a clinical trial, talk with your doctor to learn if you are eligible.

Cancer Type	Trial Name	Sponsor	Site	IRB
Breast	A011801: The COMPASSHER2 Trials ( COMprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer): CompassHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatnib.	Alliance	D/N/VBMC	NCICIRB
	A191901: Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions.	Alliance	D/N/VBMC	NCICIRB
	A012103: OptimICE-pCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy.	Alliance	D/N/VBMC	NCICIRB
	CCTG MA.39: Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive and T3N0 Breast Cancer.	CCTG	N	NCICIRB
	ASCENT-05/OptimICE-RD: A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy.	Gilead	D/N/VBMC	Advarra
	C4391022: An Interventional, Open-Label, Randomized, Multicenter Phase 3 Study Of Pf-07220060 Plus Fulvestrant Compared To Investigator’s Choice Of Therapy In Participants Over 18 Years Of Age With Hormone Receptor-Positive, Her2-Negative Advanced/Metastatic Breast Cancer Whose Disease Progressed After Prior CDK 4/6 Inhibitor Based Therapy.	Pfizer	D/N/VBMC	Advarra
	OPERA-01: OP-1250-301: A Phase 3 Radomized,Open Label Study of OP-1250 Monotherapy Vs Standard of Care For The Treatment of ER+, HER2- Advanced Or Metastatic Breast Cancer Following Endocrine And CDK 4/6 Inibitor Therapy.	Olema	D/N	Advarra
Lung	A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial.	Alliance	D/VBMC	CIRB/VIRB
	ONKORAS-101: A Phase 1a/1b Open-Label Study of BBO-8520 Monotherapy and BBO-8520 in Combination with Pembrolizumab in Subjects with Advanced KRAS G12C mutant Non-Small Cell Lung Cancer.	TheRas, Inc.	D/N	Advarra
	S2302:PRAGMATICA: A prospective randomized study Ramucirumab plus Pembrolizumab VS standard of care for participants previously treated with immunotherapy for stage IV or recurrent NSCLC.	SWOG	D/N	CIRB
	PRESERVE-003: Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors.	OncoC4	D/N/VBMC	WIRB
Skin	S2015: Melanoma Margins Trial (MelMarT): A Phase III, Multi-Centre, Multi-National Radomised Control Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma.	SWOG	VBMC	CIRB
GYN	NRG-CC008: A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk].	NRG	D/N	CIRB
	NRG-GY026: A Phase II/III Study of Paclitaxel/Carboplatin alone or combined with Either Trastuzumab and Hyaluronidase-OYSK (Herceptin Hylecta) or Pertuzumab, Trastuzumab, and Hyaluronidase-ZZXF (PHESGO) in HER2 positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma.	NRG	D/N	CIRB
	PRESERVE-004/GOG-3081: Phase 2 Randomized Open label Multicenter Study of Combination of ONC-392 and Pembrolizumab for the Trearment of Patients with Platinum Resistant Ovarian Cancer(PROC).	GOG	D/N	CIRB
	NRG-GY019: A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum.	NRG	D/N	CIRB
GU	NRG-GU010: Parallel Phase III Randomized Trials of Genomic Risk Stratified Unfavourable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation(GUIDANCE).	NRG	N	CIRB
	C2321001: A Phase I dose escalation and expanded cohort study of PF-06821497 in the treatment of adult patients with Relapsed/refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC) and follicular lymphoma (only enrolling CRPC).	Pfizer	N	WIRB
	AMG 20210081: Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Subjects With Metastatic Colorectal Cancer With KRAS p.G12C Mutation.	Amgen	D/N	Advarra
Pancreas	15-10: The Role of MicroRNAs in the Diagnosis, Prognosis and Response to Treatment in Pancreatic Cancer.	Frank	N/D/VBMC	BRANY
	16-15: Pre- and Post-Surgical Molecular Testing in Individuals with Operable Pancreatic Cancer.	Frank, Seshadri, Martignetti	N/D/VBMC	BRANY
	16-17: A Pancreatic Cancer Screening Study in High Risk Individuals.	Frank	N/D/NM	BRANY
	18-01: A Pancreatic Cancer Screening Study in High Risk Individuals Including those with Recent-Onset Diabetes Mellitus.	Frank	N/D/NM	BRANY
	A021806: A phase III trial of perioperative versus adjuvant chemotherapy for resectable pancreatic cancer.	Alliance/NRG	D/N	CIRB
	S2001: Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or BRCA2 Mutations.	SWOG/NRG	D/N	CIRB
	AMG 20230223: AMG 193 in Combination with Other Therapies in Subjects with Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous MTAP-deletion.	Amgen	D/N	WIRB
Translational	2200003 (PACT): A Prospective Study to Achieve Health Equity in Biomarker Analysis for Underrepresented Communities Receiving Cancer Treatment at Nuvance Health.	Versea	D/N/VBMC	BRAND
Observational Immunotherapy	S2013: Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study.	NRG	D/N/VBMC	CIRB
Basket Trial	C2321001: A Phase I dose escalation and expanded cohort study of PF-06821497 in the treatment of adult patients with Relapsed/refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC) and follicular lymphoma.	Pfizer	N	WIRB
	AMG 510 20190135: A Phase 1b, Master Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation.	Amgen	N	WIRB
	ONC-392-001: Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination with Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study.	OncoC4	N/D	WIRB
	NP-G2-044-P2-01: NP-G2-044-P2-01 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies.	Novita	N/D	WIRB